Regional and Country Priorities for vaccine research

Angela Hwang

A new mechanism is being established under Immunization Agenda 2030 (IA2030) to identify regional and country priorities for vaccine research and development (R&D). These priorities will inform Monitoring and Evaluation (M&E) for IA2030. They will also be disseminated widely to enable greater coordination among funders, researchers, vaccine developers, vaccine implementers, and other stakeholders.

The first question being addressed is What are regional and country priorities for vaccine product R&D? Once established, this mechanism can be used for additional questions of interest to regional and global stakeholders.

For more information, email Cette adresse e-mail est protégée contre les robots spammeurs. Vous devez activer le JavaScript pour la visualiser..

Context and results

TitreAuteurAnnéeTypeLangue
Partnering with regions and countries to identify priority pathogens for vaccinesVaccine Prioritization & Platforms Team2022PresentationAnglais

Methods

TitreAuteurAnnéeTypeLangue
Partnering with regions and countries to identify priority pathogens for vaccines: Update to PDVAC, 5 December 2022Vaccine Prioritization & Platforms Team2022PresentationAnglais
Vaccine R&D Priorities: Initial Landscaping and Proposed MethodsVaccine Prioritization & Platforms Team2022DocumentAnglais